Antiarrythmic Drugs - Long-term Follow-up in the Modern Era
This trial is active, not recruiting.
|Sponsor||University of Dundee|
|Start date||March 2010|
|End date||March 2011|
|Trial size||5000 participants|
|Trial identifier||NCT01082055, ELD006|
Antiarrhythmic drugs are associated with significant side effect profiles. Amiodarone has primarily class III action and whilst it has unrivalled efficacy in management of certain arrhythmias, it has a formidable side effect profile. Complications of continued therapy include, thyroiditis, hepatitis, cholestasis, increased skin sensitivity and pulmonary fibrosis. Current prescribing guidelines recommend frequent blood tests to monitor kidney, liver and thyroid function, in addition to frequent pulmonary function tests. Sotalol is a betablocker which possesses class III action in high doses and may predispose to QT prolongation Other class I agents such as flecainide and propafenone can be associated with sudden cardiac death in certain populations, and may predispose to other arrhythmias.
This study will examine the incidence of discontinuation of AAD therapy and adverse events.
|Observational model||ecologic or community|
time frame: 10 years
Male or female participants of any age.
Inclusion Criteria: - At least one prescription for antiarrythmic drug
|Official title||Retrospective Record Linkage Study to Investigate the Incidence of Complications and Follow-up Associated With Anti-arrythmic Drug Therapy|
Call for more information